In vivo nanotoxicology of hybrid systems based on copolymer/silica/anticancer drug

4th International Conference on Safe Production and Use of Nanomaterials

Silveira, C.P.^1 ; Paula, A.J.^2 ; Apoliná Rio, L.M.^3 ; Fávaro, W.J.^3,4 ; Durán, N.^1,4,5

Chemistry Institute, Universitáde Estadual de Campinas (UNICAMP), Campus Universitário Zeferino Vaz, s/n, Cidade Universitária, Campinas

CEP 13083-870, SP, Brazil^1

Department of Physics, Universidade Federal Do Ceará (UFC), Avenida da Universidade, Benfica, CEP 60020-181, CE, Fortaleza

2853, Brazil^2

Department of Environmental Engineering, Universidade Estadual Paulista (UNESP), Avenida Trs de Março, CEP 18087-180, SP, Sorocaba

511, Brazil^3

Farmabrasilis R and D Division, Brazil^4

Nanobioss Laboratory, Chemistry Institute, Universidade Estadual de Campinas (UNICAMP), Campus Universitário Zeferino Vaz, s/n, Cidade Universitária, Campinas

CEP 13083-870, SP, Brazil^5

关键词: Anticancer drug;    Anticancer molecules;    Cancer therapy;    Cardiotoxicity;    Mesoporous silica nanoparticles;    Multidrug resistance;    Prostate cancers;    Thermoreversible;   

Others  :  https://iopscience.iop.org/article/10.1088/1742-6596/617/1/012024/pdf
DOI  :  10.1088/1742-6596/617/1/012024

来源: IOP

【 摘 要 】

One of the major problems in cancer therapies is the high occurrence of side effects intrinsic of anticancer drugs. Doxorrubicin is a conventional anticancer molecule used to treat a wide range of cancer, such as breast, ovarian and prostate. However, its use is associated with a number of side effects like multidrug resistance and cardiotoxicity. The association with nanomaterials has been considered in the past decade to overcome the high toxicity of these drugs. In this context, mesoporous silica nanoparticles are great candidates to be used as carriers once they are very biocompatible. Taking into account the combination of nanoparticles and doxorrubicin, we treated rats with chemically induced prostate cancer with systems based on mesoporous silica nanoparticles and a thermoreversible block copolymer (Pluronic F-127) containing doxorrubicin. Preliminary results show a possible improvement in tumor conditions proportional to the concentration of the nanoparticles, opening a perspective to use mesoporous silica nanoparticles as carrier for doxorrubicin in prostate cancer treatment.